Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 120,600 shares, a growth of 100.7% from the February 28th total of 60,100 shares. Based on an average daily volume of 65,900 shares, the short-interest ratio is currently 1.8 days. Currently, 8.3% of the shares of the company are sold short.
Aptevo Therapeutics Stock Down 18.8 %
NASDAQ:APVO opened at $1.25 on Friday. The firm’s fifty day moving average is $3.38 and its two-hundred day moving average is $144.11. Aptevo Therapeutics has a one year low of $1.23 and a one year high of $184.92.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of Aptevo Therapeutics to a “sell” rating in a report on Saturday, March 15th.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Recommended Stories
- Five stocks we like better than Aptevo Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- Home Depot Stock: Is Magic Apron a Gimmick or a Game Changer?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Target Drops to COVID Lows: Buy the Dip or Cut Losses?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
